GlassScriptPhysician profile
Howard M Dubner
NPI 1760448088
$3,024.32
in general payments reported to CMS, 2019-2025
13 companies · $943 in 2025
The $943 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $59.49 · 2020: $169 · 2021: $183 · 2022: $272 · 2023: $609 · 2024: $788 · 2025: $943.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,264 · Education: $77.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,263.50 |
| Education | $77.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $919.66 | 2022-2025 | Rinvoq, Skyrizi |
| Janssen Biotech, INC. | $862.67 | 2020-2025 | Stelara, Tremfya, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $579.36 | 2019-2025 | Entyvio |
| Celltrion USA INC. | $291.59 | 2024-2025 | Vegzelma, Zymfentra |
| Genzyme Corporation | $98.87 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $56.01 | 2023-2024 | Dificid |
| Ardelyx, INC. | $51.94 | 2023 | Ibsrela |
| Celgene Corporation | $44.41 | 2024 | Zeposia |
| Fresenius Kabi USA, LLC | $34.17 | 2023 | Idacio |
| Pfizer INC. | $30.40 | 2024 | |
| Lilly USA, LLC | $21.64 | 2025 | Omvoh |
| Ironwood Pharmaceuticals, INC | $20.44 | 2024 | |
| Aimmune Therapeutics, INC. | $13.16 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Howard Dubner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.